Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313137

— · E

74d24963-2e29-5d34-81fc-aa050694984b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.540
  • MYC_TARGETS_V1+0.470
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
  • G2M_CHECKPOINT+0.450
  • MTORC1_SIGNALING+0.360
  • GLYCOLYSIS+0.300
  • MITOTIC_SPINDLE+0.290
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
  • TGF_BETA_SIGNALING+0.290
  • ANGIOGENESIS+0.270

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.320
  • ESTROGEN_RESPONSE_LATE-0.180
  • BILE_ACID_METABOLISM-0.140
  • P53_PATHWAY-0.120
  • TNFA_SIGNALING_VIA_NFKB-0.120
  • APOPTOSIS-0.080
  • ANDROGEN_RESPONSE-0.060
  • FATTY_ACID_METABOLISM-0.060
  • APICAL_SURFACE-0.050
  • KRAS_SIGNALING_DN-0.020

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR12202482
bladder-landscape@3
——0.854
2BS_7327SDAQ
brain-umap@2
high-grade glioma—0.830
3BS_W9N9844Q
brain-umap@2
high-grade glioma—0.795
4DRR168594
bladder-landscape@3
——0.794
5TCGA-C4-A0F0-01A-12R-A10U-07
bladder-landscape@3
——0.776
6TCGA-A2-A0D2-01A-21R-A034-07
breast-umap@18
—E0.774
7726D58A7-23E0-492A-B5CE-15DCB11B0C90
brain-umap@2
——0.773
8SRR33532779
breast-umap@18
—A0.771
9TCGA-EW-A1OW-01A-21R-A144-07
breast-umap@18
—E0.770
10E24D233D-71BD-4EC2-A671-375917F24E5C
brain-umap@2
——0.765

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.540Inavolisib— uncovered
MYC_TARGETS_V10.470Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.450Inavolisib— uncovered
G2M_CHECKPOINT0.450Inavolisib— uncovered
MTORC1_SIGNALING0.360Inavolisib— uncovered
GLYCOLYSIS0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.290Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.290Inavolisib— uncovered
TGF_BETA_SIGNALING0.290Inavolisib— uncovered
ANGIOGENESIS0.270Remibrutinib— uncovered
COAGULATION0.260Binimetinib— uncovered
HYPOXIA0.250Idelalisib— uncovered
PANCREAS_BETA_CELLS0.250Cobimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.220Remibrutinib— uncovered
KRAS_SIGNALING_UP0.210Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered
ALLOGRAFT_REJECTION0.190Idelalisib— uncovered
APICAL_JUNCTION0.190Inavolisib— uncovered
SPERMATOGENESIS0.190Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered